Autoimmune Disease Therapeutics Market to Reach USD 254.60 Billion by 2034 at 7.5% CAGR | DelveInsight

DelveInsight's "Autoimmune Disease Therapeutics Market Insights, Epidemiology, and Market Forecast 2034" report delivers an in-depth understanding of the Autoimmune Disease Therapeutics market size, drivers, restraints, competitive landscape, and regional trends across North America, Europe, Asia-Pacific, and Rest of World.

Explore the intricate details of the Autoimmune Disease Therapeutics Market Report @ https://www.delveinsight.com/report-store/autoimmune-disease-therapeutics-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=akpr

Key Takeaways from Autoimmune Disease Therapeutics Market Report
• In 2026, AbbVie raised its full-year revenue outlook for Skyrizi and Rinvoq to approximately USD 21.6 billion and USD 10.2 billion, respectively, and submitted regulatory applications for Rinvoq in vitiligo and alopecia areata.
• In April 2026, Roche submitted a supplemental Biologics License Application for Gazyva (obinutuzumab) to expand its use into systemic lupus erythematosus, with an FDA decision expected in December 2026.
• In 2026, Johnson & Johnson continued to shift commercial focus toward Tremfya (guselkumab) across multiple immunology indications following loss of U.S. patent exclusivity for Stelara.
• The Autoimmune Disease Therapeutics market size is estimated at USD 132.75 billion in 2025 and is projected to reach USD 254.60 billion by 2034, growing at a CAGR of 7.5% from 2026 to 2034.
• By drug modality, the biologics segment dominated the market with a 66% share in 2025.
• By drug class, the Tumor Necrosis Factor (TNF) Inhibitors segment dominated the market with a 29% share in 2025.
• By route of administration, the subcutaneous segment dominated the market with a 54% share in 2025.
• By disease type, the Rheumatoid Arthritis (RA) segment dominated the market with a 34% share in 2025.
• By end-users, the hospitals segment accounted for a 52% share in 2025.
• North America dominated the global market with a 44% revenue share in 2025, while Asia-Pacific is the fastest-growing region.
• The Autoimmune Disease Therapeutics Companies include AbbVie, Johnson & Johnson, Pfizer, Novartis, Roche, Amgen, Eli Lilly and Company, Bristol Myers Squibb, UCB, Sanofi, and others.

Get a Free sample for the Autoimmune Disease Therapeutics Market Forecast, Size & Share Analysis Report @ https://www.delveinsight.com/sample-request/autoimmune-disease-therapeutics-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=akpr

What is Autoimmune Disease Therapeutics?
Autoimmune disease therapeutics comprise the drugs and biologic agents used to manage conditions in which the immune system mistakenly attacks the body's own tissues, including rheumatoid arthritis, psoriatic arthritis, multiple sclerosis, systemic lupus erythematosus, psoriasis, and inflammatory bowel disease. Because these disorders are chronic, relapsing, and only rarely curable, treatment is centered on long-term immune modulation rather than cure, and sponsors have progressively shifted from broad immunosuppressants toward mechanism-specific biologics and oral small molecules.

Autoimmune Disease Therapeutics Market Segmentation
• By Drug Modality: Small molecules, biologics, cell-based therapies, gene-based therapies, and others
• By Drug Class: TNF inhibitors, interleukin (IL) inhibitors, B-cell inhibitors, Janus kinase (JAK) inhibitors, and others
• By Route of Administration: Oral, intravenous (IV), subcutaneous, and others
• By Disease Type: Rheumatoid arthritis (RA), psoriatic arthritis (PsA), multiple sclerosis (MS), systemic lupus erythematosus (SLE), and others
• By End-Users: Hospitals, specialty clinics, and others
• By Geography: North America, Europe, Asia-Pacific, and Rest of World

Download the report to understand which factors are driving the Autoimmune Disease Therapeutics market trends @ https://www.delveinsight.com/report-store/autoimmune-disease-therapeutics-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=akpr

Autoimmune Disease Therapeutics Market Key Growth Drivers
Rising Global Prevalence of Autoimmune Disorders: More than 80 distinct autoimmune conditions are recognized, collectively affecting an estimated 5-9% of the world's population, with roughly a quarter of patients developing a second autoimmune disorder.
Rapid Expansion of Biologic and Targeted Oral Therapies: AbbVie's Skyrizi and Rinvoq together are expected to generate more than USD 30 billion in combined 2026 revenue, offsetting continued biosimilar erosion of legacy Humira.

Accelerating Regulatory Approvals and Label Expansions: Pfizer's Litfulo secured approval for severe alopecia areata, AbbVie has submitted applications for Rinvoq in vitiligo and alopecia areata, and Roche has advanced a supplemental application for Gazyva in systemic lupus erythematosus.

Emergence of Cell-Based and Gene-Based Therapies: CAR-T and other B-cell-depleting cell therapies are advancing in systemic lupus erythematosus and multiple sclerosis, with China emerging as the first jurisdiction to approve CAR-T therapies for lupus.
Intensifying Biosimilar Competition and Access Expansion: Legacy TNF inhibitors such as adalimumab face erosion from multiple approved U.S. biosimilars, lowering overall biologic treatment costs and expanding the treated population.
Rising Healthcare Expenditure and Improved Diagnosis: Growing healthcare expenditure and diagnostic infrastructure are shortening diagnostic delays and translating into earlier treatment initiation.

Autoimmune Disease Therapeutics Market Restraints
The high cost of biologic and targeted oral therapies, often exceeding tens of thousands of dollars annually per patient, creates significant reimbursement and access barriers, particularly in price-sensitive and emerging markets. Intensifying biosimilar and generic competition compresses originator pricing and revenue even as it expands access. Most available treatments manage symptoms and slow progression rather than cure the underlying condition, and heterogeneous patient response across mechanisms complicates treatment selection. Safety concerns, including boxed warnings for JAK inhibitors, have prompted more conservative prescribing in some populations, while lengthy regulatory pathways for cell- and gene-based therapies extend development timelines and raise costs.

Autoimmune Disease Therapeutics Market Competitive Landscape
The market is classified as Moderately Concentrated. AbbVie, Johnson & Johnson, Novartis, and Roche anchor the top tier through breadth of approved biologic and oral portfolios and deep late-stage pipelines, while UCB, Amgen, Sanofi, GSK, Biogen, Takeda, and Merck KGaA compete through mechanism differentiation, indication expansion, and dedicated cell- and gene-based therapy pipelines. Leaders operate global commercial networks supported by regional manufacturing and biosimilar production capacity, with pipeline depth in cell-based and gene-based therapies for lupus and multiple sclerosis representing a decisive competitive advantage.

Autoimmune Disease Therapeutics Market Regional Insights
North America accounted for 44% of global market revenue in 2025, reflecting a mature immunology treatment ecosystem, deep clinical-research infrastructure, and broad payer coverage of biologics, particularly in the United States. Europe is supported by established EMA regulatory frameworks and a deep base of immunology manufacturers including UCB, Sanofi, Novartis, and Roche. Asia-Pacific is the fastest-growing region, propelled by rising autoimmune disease diagnoses, expanding healthcare infrastructure, and growing biologic and biosimilar adoption across China, Japan, India, South Korea, and Australia. The Rest of World region, spanning Latin America, the Middle East, and Africa, is an emerging growth frontier supported by expanding healthcare infrastructure and growing access to biosimilar therapies.

Discover more about companies working in the Autoimmune Disease Therapeutics market @ https://www.delveinsight.com/sample-request/autoimmune-disease-therapeutics-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=akpr

Autoimmune Disease Therapeutics Market Outlook
Treatment of autoimmune disease has shifted from broad immunosuppressants toward mechanism-specific biologics and targeted oral therapies. Biologics dominate the modality mix, led by TNF inhibitors alongside a fast-growing base of IL inhibitors, B-cell inhibitors, and JAK inhibitors, with subcutaneous self-administration increasingly preferred over infusion-based delivery. Rheumatoid arthritis remains the largest diagnosed disease segment, while multiple sclerosis and systemic lupus erythematosus are emerging as the fastest-growing indications as B-cell-depleting, interferon-pathway, and cell-based therapies reach patients with previously limited options. Continued label expansions, biosimilar penetration, and the maturation of CAR-T and other cell- and gene-based modalities are expected to sustain steady, high-single-digit growth through 2034.

Scope of the Autoimmune Disease Therapeutics Market Report
• Study Period: Market size reported for 2025, forecast through 2034
• Forecast Period: 2026-2034
• Coverage: North America, Europe, Asia-Pacific, and Rest of World
• Autoimmune Disease Therapeutics Companies: AbbVie, Johnson & Johnson, Pfizer, Novartis, Roche, Amgen, Eli Lilly and Company, Bristol Myers Squibb, UCB, Sanofi, and others
• Autoimmune Disease Therapeutics Market Segmentation: By drug modality, drug class, route of administration, disease type, end-users, and geography
• Autoimmune Disease Therapeutics Market Dynamics: Market drivers and market restraints
• Competitive Intelligence Analysis: Market concentration, leading players, pipeline depth, and label expansion strategy

To know more about Autoimmune Disease Therapeutics companies working in the treatment market, visit @ https://www.delveinsight.com/sample-request/autoimmune-disease-therapeutics-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=akpr

Table of Contents
1. Autoimmune Disease Therapeutics Market Report Introduction
2. Autoimmune Disease Therapeutics Market Executive Summary
3. Autoimmune Disease Therapeutics Market Key Factors Analysis
4. Impact Analysis: AI, Geopolitical, Trade, and Economic Developments
5. Regulatory Analysis
6. Autoimmune Disease Therapeutics Market Porter's Five Forces Analysis
7. Autoimmune Disease Therapeutics Market Assessment
8. Autoimmune Disease Therapeutics Market Competitive Landscape
9. Autoimmune Disease Therapeutics Market Startup Funding and Investment Trends
10. Autoimmune Disease Therapeutics Market Company and Product Profiles
11. Autoimmune Disease Therapeutics Report KOL Views
12. Project Approach
13. About DelveInsight
14. Disclaimer and Contact Us

Company Name: DelveInsight Business Research LLP
Contact Person: Abhishek kumar
Email: info@delveinsight.com
Phone: 9650213330
Address: 304 S. Jones Blvd #2432
City: Las Vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com

About Us
DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.

This release was published on openPR.